Y Intercept Hong Kong Ltd Sells 723,540 Shares of Amicus Therapeutics, Inc. $FOLD

Y Intercept Hong Kong Ltd lessened its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 73.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 263,239 shares of the biopharmaceutical company’s stock after selling 723,540 shares during the period. Y Intercept Hong Kong Ltd owned about 0.09% of Amicus Therapeutics worth $2,074,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in FOLD. Strs Ohio bought a new position in Amicus Therapeutics during the 1st quarter valued at about $30,000. Osaic Holdings Inc. boosted its holdings in shares of Amicus Therapeutics by 450.1% in the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 3,358 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Amicus Therapeutics by 472.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 3,677 shares during the last quarter. Versant Capital Management Inc increased its holdings in Amicus Therapeutics by 499.1% during the 3rd quarter. Versant Capital Management Inc now owns 5,266 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 4,387 shares in the last quarter. Finally, CWM LLC raised its position in Amicus Therapeutics by 395.9% in the 2nd quarter. CWM LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 7,502 shares during the last quarter.

Insiders Place Their Bets

In other news, insider Ellen Rosenberg sold 23,621 shares of the stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $10.00, for a total transaction of $236,210.00. Following the completion of the sale, the insider owned 507,710 shares of the company’s stock, valued at $5,077,100. This represents a 4.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bradley L. Campbell sold 75,000 shares of Amicus Therapeutics stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $14.31, for a total value of $1,073,250.00. Following the completion of the sale, the chief executive officer directly owned 1,021,180 shares in the company, valued at $14,613,085.80. This represents a 6.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 420,450 shares of company stock valued at $4,730,250 in the last quarter. 2.20% of the stock is owned by company insiders.

Amicus Therapeutics Price Performance

Amicus Therapeutics stock opened at $14.28 on Thursday. The company has a current ratio of 2.99, a quick ratio of 2.09 and a debt-to-equity ratio of 1.70. The firm has a market capitalization of $4.48 billion, a P/E ratio of -356.91 and a beta of 0.42. The business has a 50-day moving average of $12.51 and a 200-day moving average of $9.46. Amicus Therapeutics, Inc. has a 1 year low of $5.51 and a 1 year high of $14.38.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.05. The business had revenue of $169.06 million for the quarter, compared to analyst estimates of $165.24 million. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. Amicus Therapeutics’s quarterly revenue was up 19.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.10 EPS. On average, equities analysts anticipate that Amicus Therapeutics, Inc. will post 0.15 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on FOLD. Needham & Company LLC lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 19th. Zacks Research lowered shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday. Citigroup restated a “neutral” rating and issued a $14.50 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Monday, December 22nd. JPMorgan Chase & Co. increased their price objective on Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Finally, Leerink Partners cut Amicus Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $17.00 to $14.50 in a research note on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Amicus Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $15.55.

Amicus Therapeutics Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.